Publication | Closed Access

Camrelizumab plus apatinib as second-line treatment for advanced oesophageal squamous cell carcinoma (CAP 02): a single-arm, open-label, phase 2 trial

Second-line TreatmentOncologyEsophageal CancerGastrointestinal OncologyCap 02PathologyCancer TreatmentMedicineRadiation Oncology